Imagine glasses that act like a camera lens, automatically zooming in and out as you look from your phone to the horizon. They use tiny sensors to measure how far away an object is and instantly change the liquid inside the lens to keep everything sharp. It removes the need for those annoying progressive lenses that often cause headaches or neck pain.
Standard progressive lenses cause vision discomfort and postural pain for 20% of users. This leads to decreased work efficiency and increased health costs for an aging global population.
A pair of autofocusing eyeglasses featuring distance-sensing ToF sensors, fluidic micro-actuators, and variable fluidic lenses that adapt optical correction in real-time.
If you are an optician dealing with the 20% of progressive lens wearers who experience vision discomfort—this project developed autofocusing eyeglasses that provide a trial mount for customers to test the comfort in-store. This allows for a BtoBtoC sales model with a product that can be recalibrated as the user ages.
If you are a lens manufacturer dealing with the limitations of static prescriptions—this project developed a fluidic micro-actuator system that converts pressure into optical correction. This creates a Class 1 medical device capable of real-time adaptation to the user's distance needs.
If you are a health provider dealing with musculoskeletal problems and visual fatigue in aging employees—this project developed adaptive eyeglasses that prevent postural pains caused by inadequate ergonomics. This helps maintain efficiency for the 2 billion people worldwide affected by presbyopia.
Based on available project data, specific pricing is not mentioned, but the business model is BtoBtoC via opticians, featuring a recalibration service to avoid the need for frequent expensive replacements.
The I-SEE project specifically aims to launch the first commercial product on the market, moving from the current developed technology to a wide range of commercial activities.
Laclarée owns the technology, which is protected by patents and trade secrets.
The eyeglasses are categorized as a class 1 medical device.
The project period is from 2024-12-01 to 2026-11-30, focusing on launching the first commercial product.
The project is led by a single French SME, Laclarée, with a 100% industry ratio. This lean structure suggests a highly focused commercial drive, as the company owns the IP and is utilizing the EUR 2,499,999 EU contribution to move directly toward market launch without the overhead of academic partners.
Contact Laclarée in France for B2B partnership opportunities in the optical sector.
Contact us to explore licensing or distribution partnerships for adaptive optical technologies.
